CIBA-GEIGY's ESTRADERM (ESTRODIAL) TRANSDERMAL PATCH
Executive Summary
CIBA-GEIGY's ESTRADERM (ESTRODIAL) TRANSDERMAL PATCH for treatment of menopausal symptoms was approved by FDA Sept. 10. The product is available in dosages of 0.05 mg and 0.1 mg to be applied twice weekly. Estraderm is Ciba-Geigy's third transdermal patch product utilizing Alza's delivery system. Ciba's Transderm Scop (scopolamine) was the first transdermal product on the market, followed by three nitroglycerin patches, of which Transderm-Nitro is the market leader. Estraderm is the third drug class to be made available in a transdermal delivery system. Boehringer Ingelheim's antihypertensive Catapres (clonidine) is the only other product line besides nitroglycerin. Ciba-Geigy obtained approval for Estraderm two years after an NDA submission in August 1984. FDA's Fertility and Maternal Health Drugs Advisory Cmte. recommended it for approval last December. The transdermal estrogen product is currently in clinicals for osteoporosis.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth